Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Administration KIT----1件: 19 💬
2Administration OF A high dose OF desipramine----1件: 156 💬
3Administration OF A LOW dose OF desipramine----1件: 156 💬
4Administration OF AN ACE-inhibitor or NOT----1件: 210 💬
5Administration OF carbidopa/levodopa----2件: 6, 17 💬
6Administration OF drug (interferon-gamma 1-B) subcutaneously----1件: 65 💬
7Administration OF methylprednisolone + prednisone + mycophenolate mofetil----1件: 49 💬
8Administration OF methylprednisolone, paracetamol and dexchlorpheniramine----1件: 49 💬
9Administration OF rituximab and methylprednisolone----1件: 51 💬
10Avandia administration FOR 6-12 weeks----1件: 265 💬
11BMN 111 administration VIA injector PEN----1件: 276 💬
12BMN 111 administration VIA vial and syringe----1件: 276 💬
13Bosentan administration1件: Bosentan2件: Bosentan ,
Bosentan 💬 		2件: EDNRA,
EDNRB 💬 		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86 💬
14CRH administration----2件: 72, 78 💬
15CS1 administration----1件: 86 💬
16Docosahexaenoic acid administration: 50 MG/KG/DAY during 12 months1件: Doconexent---1件: 299 💬
17Eculizumab administration1件: Eculizumab1件: Eculizumab 💬 1件: C5 💬 11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 13 💬
18Efgartigimod administration----1件: 11 💬
19Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration OF unlabeled vedolizumab1件: Vedolizumab1件: Vedolizumab 💬 2件: ITGA4,
ITGB7 💬 		16件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬2件: 96, 97 💬
20Fluorescence molecular imaging procedure without prior administration OF vedolizumab-800CW1件: Vedolizumab1件: Vedolizumab 💬 2件: ITGA4,
ITGB7 💬 		16件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬2件: 96, 97 💬
21GLP1-RA (exenatide) administration----2件: 72, 78 💬
22Historical data OF lipid-lowering drug administration----1件: 79 💬
23Home administration----1件: 77 💬
24Human normal immunoglobulin FOR intravenous (IV) administration1件: Human immunoglobulin G1件: Globulin, immune 💬 --1件: 51 💬
25Human normal immunoglobulin FOR intravenous administration1件: Human immunoglobulin G1件: Globulin, immune 💬 --3件: 14, 51, 65 💬
26Human normal immunoglobulin FOR subcutaneous administration1件: Human immunoglobulin G1件: Globulin, immune 💬 --2件: 51, 65 💬
27Immune globulin (human) 10% solution FOR intravenous administration----1件: 14 💬
28Interlaminar ultrasound-assisted intrathecal administration OF nusinersen----1件: 3 💬
29Intracerebral administration OF aavrh.10cuarsa----1件: 19 💬
30Intrathalamic AAV.pgrn administration----1件: 127 💬
31Intrathecal administration OF autologous MSC-NP----1件: 13 💬
32Intravenous administration OF 1 million OF MSC----1件: 2 💬
33Intravenous administration OF 2 million OF MSC----1件: 2 💬
34Intravenous administration OF 4 million OF MSC----1件: 2 💬
35Intravenous administration OF ferric carboxymaltose----1件: 86 💬
36IV methylprednisolone administration1件: Methylprednisolone2件: Methylprednisolone ,
Methylprednisolone acetate 💬 		1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 13 💬
37JWK007 single intravenous infusion administration----1件: 113 💬
38JWK008 single intravenous infusion administration----1件: 19 💬
39Landmark-based intrathecal administration OF nusinersen----1件: 3 💬
40Levodopa (drug), intraduodenal administration1件: Levodopa1件: Levodopa 💬 5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬 		13件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
41Levodopa/carbidopa solution FOR SC administration1件: Levodopa1件: Levodopa 💬 5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬 		13件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
42LOW-dose IL-2 administration----1件: 96 💬
43Methotrexate + targeted therapy administration1件: Methotrexate2件: Methotrexate ,
Methotrexate sodium 💬 		2件: DHFR,
DHFR 💬 		3件: Folate biosynthesis, Folate transport and metabolism, One carbon pool by folate 💬1件: 46 💬
44Methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration1件: Methotrexate2件: Methotrexate ,
Methotrexate sodium 💬 		2件: DHFR,
DHFR 💬 		3件: Folate biosynthesis, Folate transport and metabolism, One carbon pool by folate 💬1件: 46 💬
45Nirs after bosentan administration----1件: 13 💬
46Normal saline IV administration----1件: 65 💬
47Obinutuzumab administration1件: Obinutuzumab1件: Obinutuzumab 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 49 💬
48Oral administration OF 100 MG KH176 twice daily----1件: 21 💬
49Oxygen administration1件: Oxygen1件: Oxygen 💬 --1件: 88 💬
50QR-313 GEL FOR topical (cutaneous) administration1件: QR-313---1件: 36 💬
51Questionnaire administration----7件: 16, 28, 34, 51, 60, 97, 298 💬
52RAAV1-CMV-GAA (study agent) administration----1件: 256 💬
53Routine steroid administration group----1件: 85 💬
54Semi continuous intra-oral administration OF LD/CD----1件: 6 💬
55SUB-retinal administration OF OCU400-301----1件: 90 💬
56Subcutaneous administration OF recombinant human IGF-1----1件: 77 💬
57Subcutanious administration----1件: 46 💬
58Subretinal administration OF RAAV2-VMD2-hmertkrecombinant adeno-associated virus----1件: 90 💬
59Survey administration----1件: 28 💬
60TCD after bosentan administration----1件: 13 💬
61Tobramycin time OF administration1件: Tobramycin2件: Tobramycin ,
Tobramycin sulfate 💬 		--1件: 299 💬